Core Viewpoint - The stock of CSPC Pharmaceutical Group (01093) has risen over 4%, currently trading at HKD 9.83 with a transaction volume of HKD 899 million, following the acceptance of its上市申请 for the Ploglitazone Metformin Sustained Release Tablets by the National Medical Products Administration of China [1] Group 1: Company Developments - CSPC Pharmaceutical Group is actively advancing the clinical development of a combination therapy consisting of Ploglitazone, Dapagliflozin, and Metformin to benefit more patients [1] - Ploglitazone is a Dipeptidyl Peptidase-4 (DPP-4) inhibitor that increases endogenous active GLP-1 levels, enhancing insulin secretion in response to glucose and improving hyperglycemia [1] - Metformin is a biguanide that reduces hepatic glucose production, inhibits intestinal glucose absorption, and increases insulin sensitivity by enhancing peripheral glucose uptake and utilization [1]
港股异动 | 石药集团(01093)涨超4% 普卢格列汀二甲双胍缓释片上市申请获受理 积极推进三药联合临床开发